Class / Patent application number | Description | Number of patent applications / Date published |
424160100 | Immunodeficiency virus | 33 |
20090081235 | PSEUDOMONAS EXOTOXIN A-LIKE CHIMERIC IMMUNOGENS FOR ELICITING A SECRETORY IGA-MEDIATED IMMUNE RESPONSE - This invention provides methods of eliciting a secretory IgA-mediated immune response in a subject by administering a | 03-26-2009 |
20090098144 | IMMUNOGEN PRESENTING HIV GP120 V3 LOOP IN A CONFORMATION THAT INDUCES BROADLY NEUTRALIZING ANTIBODIES - Insertion of HIV-1 V3 loop peptides from the viral glycoprotein gp120 into selected, immunogenic scaffold proteins results in a recombinant polypeptide that is a potent V3 immunogen. V3 immunogens include natural and consensus V3 sequences and cyclic and reverse peptides. Preferred scaffold proteins are Cholera Toxin subunit B and homologues thereof including closely related | 04-16-2009 |
20090169567 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF - A compound represented by general formula (I): | 07-02-2009 |
20090214569 | Use of HIV envelope/CD4 complexes for the generation antibodies - The instant invention provides antibodies, vaccines, and immunogenic compositions, for the treatment and prevention of HIV infection. The invention further provides kits comprising the antibodies, vaccines and immunogenic compositions, of the invention. | 08-27-2009 |
20090232830 | Modified HIV-1 Envelope Proteins - The present invention relates to modified HIV-1 envelope proteins which express epitopes that produce a broadly cross reactive neutralizing response, their methods of use and antibodies which bind to these epitopes. | 09-17-2009 |
20090232831 | METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION - A conserved cluster of oligomannose glycans on gp120 has been identified as the epitope recognized by the broadly HIV-1-neutralizing monoclonal antibody 2G12. Oligomannose glycans are also the ligands for DC-SIGN, a C-type lectin found on the surface of dendritic cells. Multivalency is fundamental for carbohydrate-protein interactions, and mimicking of the high glycan density on the virus surface has become essential for designing carbohydrate-based HIV vaccines and antiviral agents. Synthesis of oligomannose dendrons, which display multivalent oligomannoses in high density, and characterize their interaction with 2G12 and DC-SIGN by a glycan microarray binding assay is disclosed. These glycodendrons inhibit the binding of gp120 to 2G12 and recombinant dimeric DC-SIGN with IC | 09-17-2009 |
20100104580 | Altered Immunogenic Landscape in HIV-1 Envelope Proteins - The present invention provides compositions and methods useful in the prevention and treatment of HIV-1 infection in a host subject. High affinity binding of an allosteric dual antagonist to HIV-1 gp120 induces a conformational change in the gp 120 protein that traps the gp 120 protein in a three-dimensional structure that suppresses its function and exposes novel antigenic epitopes to host immune surveillance. | 04-29-2010 |
20100196397 | Five-helix protein - Five-Helix protein, which comprises the three N-helices and at least two, but not three, of the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, such as amino acid residue linkers, is disclosed. Six-Helix protein, which includes the three N-helices and the three C-helices of the trimer-of-hairpin structure of HIV gp41, separated by linkers, is also disclosed. | 08-05-2010 |
20100221259 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF - The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. | 09-02-2010 |
20100303829 | HIV VPR-SPECIFIC T CELL RECEPTORS - The instant invention provides TCRs having one or more amino acid substitutions that bind to the AL9 epitope of the HIV protein vpr (AIIRILQQL (SEQ ID NO: 1)). | 12-02-2010 |
20110086041 | Fusion-Intermediate State of HIV-1 gP41 Targeted by Broadly Neutralizing Antibodies - Isolated, antigenic polypeptides including a prehairpin intermediate conformation of gp41 and vectors encoding such polypeptides are provided. Antibodies that bind to a prehairpin intermediate conformation of gp41 and methods of making antibodies a that bind to prehairpin intermediate conformation of gp41 are also provided. Vaccines against a prehairpin intermediate conformation of gp41, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. Methods of screening compounds that bind to an isolated, prehairpin intermediate conformation of gp41 are further provided. | 04-14-2011 |
20110142856 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF - The present invention relates to a compound represented by formula (I-0): | 06-16-2011 |
20110212106 | HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF - The invention relates to antibodies and antigen binding fragments thereof that neutralize HIV-1 infection. The invention also relates to nucleic acids that encode, immortalized B cells and cultured plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of HIV-1 infection. | 09-01-2011 |
20120100156 | Therapeutic Agent - Anti-HLA and other antibodies are present in goat serum after injection of HIV antigenic material, and form the basis for a most surprisingly effective treatment of HIV, multiple sclerosis and other conditions. | 04-26-2012 |
20120156219 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF - The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. | 06-21-2012 |
20120207765 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF - A compound represented by general formula (I): | 08-16-2012 |
20120225083 | VIRAL POLYPEPTIDES AND METHODS - The invention is directed to polypeptides and polypeptide fragments from HIV-1 envelope (Env) proteins following the characterization of Env structures from environments where HIV isolates expose conserved neutralization-sensitive Env structures. There is provided a polypeptide being all or a fragment of an HIV-1 envelope protein from a transmission strain of HIV-1, the polypeptide having neutralization sensitive epitopes that are accessible. | 09-06-2012 |
20120269821 | HIV-1 ANTIBODIES - The present invention relates, in general, to HIV-1 antibodies and, in particular, to broadly neutralizing HIV-1 antibodies that target the gp41 membrane-proximal external region (MPER). | 10-25-2012 |
20120328627 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF - The present invention relates to a compound represented by formula (I): | 12-27-2012 |
20130011414 | BROADLY CROSS-REACTIVE HIV-1-SPECIFIC ANTIBODIES FOR PREVENTION AND TREATMENT OF HIV - Provided herein are HIV-1-specific transforming antibodies (tAbs) and antigens that are recognized by HIV-1-specific tAbs. Also provided herein are methods for screening and/or generating HIV-1-specific tAbs and uses of tAbs for prevention and treatment of HIV-1 infection. | 01-10-2013 |
20130022619 | METHODS AND COMPOSITIONS FOR INHIBITING HIV TRANSMISSION - The present invention provides methods and compositions useful in the field of medicine, and particularly in the treatment of viral infections. More particularly, the invention relates to the use of methods and compositions for the inhibition of human immunodeficiency virus (HIV) transmission. | 01-24-2013 |
20130071406 | Methods and Compositions for Treatment of Human Immunodeficiency Virus Infection with Conjugated Antibodies or Antibody Fragments - The present invention concerns methods and compositions for treatment of HIV infection in a subject. The compositions may comprise a targeting molecule against an HIV antigen, such as an anti-HIV antibody or antibody fragment. The anti-HIV antibody or fragment may be conjugated to a variety of cytotoxic agents, such as doxorubicin. In a preferred embodiment, the antibody or fragment is P4/D10. Other embodiments may concern methods of imaging, detection or diagnosis of HIV infection in a subject using an anti-HIV antibody or fragment conjugated to a diagnostic agent. In alternative embodiments, a bispecific antibody with at least one binding site for an HIV antigen and at least one binding site for a carrier molecule may be administered, optionally followed by a clearing agent, followed by administration of a carrier molecule conjugated to a therapeutic agent. | 03-21-2013 |
20140072576 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF - The present invention relates to a compound represented by formula (I): | 03-13-2014 |
20140112936 | METHODS OF NEUTRALIZING VIRAL INFECTION - Isolated, antigenic polypeptides including a pre-hairpin intermediate conformation of gp41 and vectors encoding such polypeptides are provided. Antibodies that bind to a pre-hairpin intermediate conformation of gp41 and methods of making antibodies a that bind to pre-hairpin intermediate conformation of gp41 are also provided. Vaccines against a pre-hairpin Fd intermediate conformation of gp41, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. Methods of screening compounds that bind to an isolated, pre-hairpin intermediate conformation of gp41 are further provided. | 04-24-2014 |
20140178406 | USE OF GOAT SERUM FOR VETERINARY TREATMENT - Methods for veterinary treatment of mammals are described, for treatment of conditions having an inflammatory component. The methods are particularly suited to treatment of cats, dogs, or horses. | 06-26-2014 |
20140234337 | ANTIBODY AND ANTIBODY-CONTAINING COMPOSITION - For many diseases due to microbes or the like, proliferation of microbes themselves is a cause of a symptom. However, there were cases where a substance released by the microbes is a cause of a symptom. In such cases, when attempting to treat a disease with an antibody, it was necessary to obtain an antibody against an antigen that is a substance causing the disease. However, it was difficult to find the underlying substance causing the disease among substances released by the microbes. An antibody (polyclonal) binding to not only an antigen but also to a substance, which is secreted by the antigen and accelerates the deterioration of a symptom, is obtained by immunizing birds with a lysis solution produced from lysing microbial cells as an antigen. Further, an antibody obtained with a surface protein of a virus as an antigen is expected to inhibit an infection by a virus. | 08-21-2014 |
20140255426 | WNT PATHWAY INHIBITORS FOR TREATING VIRAL INFECTIONS - In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection comprising administering an effective amount of a Wnt pathway inhibitor optionally in combination with one or more anti-viral agents. In certain embodiments, the subject is diagnosed with a chronic viral infection such as human immunodeficiency virus (HIV). | 09-11-2014 |
20140328862 | HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF - The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection. | 11-06-2014 |
20150010578 | DELIVERY OF PROTEINS USING ADENO-ASSOCIATED VIRUS (AAV) VECTORS - Disclosed herein are compositions, systems and methods for delivery of proteins of interest using adeno-associated virus (AAV) vectors. | 01-08-2015 |
20150368661 | METHODS FOR PRODUCING ANTIBODIES - Methods for producing antibodies are provided and include transforming a plant cell with a nucleic acid encoding a heavy chain of an antibody, a light chain of an antibody, and a linking polypeptide connecting the heavy chain to the light chain. The nucleic acid is then expressed in the plant cell, such that, upon expression the linking polypeptide is cleaved to separate the heavy chain from the light chain. Isolated nucleic acid sequences, expression vectors, and transformed plant cells useful for producing the antibodies are also provided. Further provided are methods for treating a viral infection and include the steps of obtaining an antibody produced by the above-described methods and then administering the antibody to a subject. | 12-24-2015 |
20160008374 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | 01-14-2016 |
20160039913 | THE USE OF ANTIBODIES IN TREATING HIV INFECTION AND SUPPRESSING HIV TRANSMISSION - In one aspect, the disclosure provides methods of treating HIV and decreasing the chance of HIV infection in a subject, and compositions used in these methods. | 02-11-2016 |
20170233335 | INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | 08-17-2017 |